194 results on '"Zheng, Yinggan"'
Search Results
2. Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction With Cardiogenic Shock and Prolonged Interhospital Transport Times
3. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial
4. Abstract 14391: Biomarkers, Proteomics, and Echocardiography Lend Insights into Cardiovascular Death in HFrEF: A VICTORIA Substudy
5. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
6. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
7. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat
8. Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial
9. Abstract 11574: Relationship Between Baseline Electrocardiographic Parameters and Outcomes in Patients With High-Risk Heart Failure With Reduced Ejection Fraction: Insights From the Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
10. Abstract 11453: Age, Sex, and Outcomes in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
11. Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes
12. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
13. NT-PROBNP DURING SCREENING IN THE STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL: INSIGHTS INTO OUTCOMES AND VERICIGUAT
14. Abstract 15589: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in People With Type 2 Diabetes Mellitus and Vascular Disease: A Tecos Substudy
15. Abstract 14727: Meteorin-like Glial Cell Differentiation Regulator is a Novel Protein Biomarker of Cardiovascular Outcomes in Patients With Diabetes and Vascular Disease: A TECOS Substudy
16. Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.
17. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry
18. Changes in dietary intake and nutritional status associated with a significant reduction in sodium intake in patients with heart failure. A sub-analysis of the SODIUM-HF pilot study
19. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
20. Predictors and associated clinical outcomes of low cardiac output syndrome following cardiac surgery: insights from the LEVO-CTS trial
21. Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction
22. Dietary fatty acids intake and mortality in patients with heart failure
23. Relationships Between Baseline Q Waves, Time From Symptom Onset, and Clinical Outcomes in ST-Segment–Elevation Myocardial Infarction Patients: Insights From the Vital Heart Response Registry
24. EJECTION FRACTION, BIOMARKERS, AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION AND THE IMPACT OF VERICIGUAT ON OUTCOMES IN THE VICTORIA TRIAL
25. Using Cochran's Z Statistic to Test the Kernel-Smoothed Item Response Function Differences between Focal and Reference Groups
26. Using the Attribute Hierarchy Method to Identify and Interpret Cognitive Skills that Produce Group Differences
27. Corrigendum to “Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial” [Am Heart J 169/6 (2015) 890–898]
28. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
29. Using the Attribute Hierarchy Method to Identify and Interpret Cognitive Skills That Produce Group Differences
30. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
31. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
32. Remote ischaemic conditioning in ST elevation myocardial infarction: a registry-based randomised trial
33. Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST ‐segment elevation myocardial infarction
34. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial
35. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial
36. Remote ischaemic conditioning in ST elevation myocardial infarction: a registry-based randomised trial.
37. Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex
38. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial
39. The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): A pilot study
40. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
41. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial
42. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial
43. Procedural Volume and Outcomes After Primary Percutaneous Coronary Intervention for ST‐Segment–Elevation Myocardial Infarction in Kerala, India: Report of the Cardiological Society of India–Kerala Primary Percutaneous Coronary Intervention Registry
44. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
45. Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non–ST-segment elevation acute coronary syndromes
46. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
47. ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY
48. APPLICATION OF TICAGRELOR OR CLOPIDOGREL BASED DUAL ANTIPLATELET THERAPY FOLLOWING A PHARMACOINVASIVE STRATEGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE VITAL HEART RESPONSE REGISTRY
49. Utilization and Costs of Noninvasive Cardiac Tests After Acute Coronary Syndromes: Insights From the Alberta COAPT Study
50. Comparison of Angiotensin‐Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.